Analyst Research

Report Title Price
Provider: GlobalData
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

H Lundbeck A/S and Takeda Pharmaceutical Company Limited's Vortioxetine Clinical Phase III Data Show Improvement in Symptoms of Major Depression

Saturday, 18 May 2013 12:00pm EDT 

H Lundbeck A/S and Takeda Pharmaceutical Company Limited announced that Vortioxetine clinical phase III data show improvement in symptoms of major depressive disorder (MDD) - commonly referred to as major depression. The studies demonstrate efficacy at doses of 15 mg and 20 mg per day including an improvement of overall functioning. The phase III data will be presented at the 2013 Annual Meeting of the American Psychiatric Association (APA) in San Francisco, USA.